FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3120520904> ?p ?o ?g. }

• W3120520904 endingPage "274" @default.
• W3120520904 startingPage "260" @default.
• W3120520904 abstract "Abstract Objective To reduce the toxicity and side effects of arsenic trioxide (ATO) and provide a new approach for the treatment of primary liver cancer, a folic acid-modified calcium arsenite liposomal “target-controlled” drug delivery system (FA-LP-CaAs) was fabricated using the reverse microemulsion method. Methods A Malvern particle size analyzer and a transmission electron microscope were employed to determine the particle size, distribution, zeta potential and morphology of FA-LP-CaAs. Further, inductively coupled plasma emission spectrometry was employed to determine the drug loading capacity, entrapment efficiency, and in vitro release behavior of FA-LP-CaAs. To determine its toxicity in human hepatoma cells (HepG2) and human normal hepatocytes (LO2) and its effect on HepG2 cell cycle and apoptosis, the MTT method was used. Laser confocal and flow cytometry were also employed to determine the uptake of FA-LP-CaAs by cells. After establishing a mouse liver cancer model, the in vivo distribution of the drug included in the formulation was investigated using in vivo fluorescence. To evaluate the liver cancer targeting and anti-tumor effects of FA-LP-CaAs in vivo, the distribution of ATO in tissues and changes in tumor volume and body weight after liposomal administration were investigated using hematoxylin-eosin (HE)-stained tumor sections. Results The particle size, zeta potential and PDI of FA-LP-CaAs were (122.67 ± 2.18) nm, (12.81 ± 0.75) mV and 0.22 ± 0.01, respectively, while its drug loading capacity was 18.49% ± 1.14%. In vitro experimental results revealed that FA-LP-CaAs had a strong killing effect on HepG2 cells. Further, the cell uptake capacity of this formulation was found to improve. Based on in vivo assessments, FA-LP-CaAs could significantly increase the distribution of ATO in tumor sites and inhibit tumor growth. Conclusions Herein, an FA-LP-CaAs formulation was successfully fabricated. This liposomal drug delivery system had a round appearance, uniform particle size, good polydispersity coeffi-cient, evident “core-shell” structure, high drug loading capacity and pH response, tumor targeted drug delivery and sustained drug release. These findings support further research and the application of ATO as an anti-liver cancer prodrug and provide a new method for the treatment of liver cancer." @default.
• W3120520904 created "2021-01-18" @default.
• W3120520904 creator A5023957648 @default.
• W3120520904 creator A5025904795 @default.
• W3120520904 creator A5049912026 @default.
• W3120520904 creator A5056232699 @default.
• W3120520904 creator A5063689514 @default.
• W3120520904 creator A5066475302 @default.
• W3120520904 creator A5078983941 @default.
• W3120520904 creator A5082063900 @default.
• W3120520904 date "2020-12-01" @default.
• W3120520904 modified "2023-09-26" @default.
• W3120520904 title "Fabrication of A Folic Acid-Modified Arsenic Trioxide Prodrug Liposome and Assessment of its Anti-Hepatocellular Carcinoma Activity" @default.
• W3120520904 cites W1584739834 @default.
• W3120520904 cites W1692919389 @default.
• W3120520904 cites W1965712234 @default.
• W3120520904 cites W1967410304 @default.
• W3120520904 cites W1968143647 @default.
• W3120520904 cites W1995980440 @default.
• W3120520904 cites W2002015794 @default.
• W3120520904 cites W2002721997 @default.
• W3120520904 cites W2004080090 @default.
• W3120520904 cites W2010680800 @default.
• W3120520904 cites W2017289228 @default.
• W3120520904 cites W2041187942 @default.
• W3120520904 cites W2042949277 @default.
• W3120520904 cites W2043534420 @default.
• W3120520904 cites W2046528901 @default.
• W3120520904 cites W2072971495 @default.
• W3120520904 cites W2085990252 @default.
• W3120520904 cites W2092738402 @default.
• W3120520904 cites W2094442197 @default.
• W3120520904 cites W2107578355 @default.
• W3120520904 cites W2127833150 @default.
• W3120520904 cites W2133786616 @default.
• W3120520904 cites W2155717682 @default.
• W3120520904 cites W2160395831 @default.
• W3120520904 cites W2170325085 @default.
• W3120520904 cites W2332121914 @default.
• W3120520904 cites W2342204587 @default.
• W3120520904 cites W2344361295 @default.
• W3120520904 cites W2396730683 @default.
• W3120520904 cites W2520390708 @default.
• W3120520904 cites W2575996135 @default.
• W3120520904 cites W2605814520 @default.
• W3120520904 cites W2615824666 @default.
• W3120520904 cites W2752351281 @default.
• W3120520904 cites W2768751537 @default.
• W3120520904 cites W2780453723 @default.
• W3120520904 cites W2789759944 @default.
• W3120520904 cites W2792651577 @default.
• W3120520904 cites W2918095490 @default.
• W3120520904 cites W2969802526 @default.
• W3120520904 cites W4247050894 @default.
• W3120520904 doi "https://doi.org/10.1016/j.dcmed.2020.12.005" @default.
• W3120520904 hasPublicationYear "2020" @default.
• W3120520904 type Work @default.
• W3120520904 sameAs 3120520904 @default.
• W3120520904 citedByCount "3" @default.
• W3120520904 countsByYear W31205209042022 @default.
• W3120520904 countsByYear W31205209042023 @default.
• W3120520904 crossrefType "journal-article" @default.
• W3120520904 hasAuthorship W3120520904A5023957648 @default.
• W3120520904 hasAuthorship W3120520904A5025904795 @default.
• W3120520904 hasAuthorship W3120520904A5049912026 @default.
• W3120520904 hasAuthorship W3120520904A5056232699 @default.
• W3120520904 hasAuthorship W3120520904A5063689514 @default.
• W3120520904 hasAuthorship W3120520904A5066475302 @default.
• W3120520904 hasAuthorship W3120520904A5078983941 @default.
• W3120520904 hasAuthorship W3120520904A5082063900 @default.
• W3120520904 hasBestOaLocation W31205209041 @default.
• W3120520904 hasConcept C108215921 @default.
• W3120520904 hasConcept C126322002 @default.
• W3120520904 hasConcept C178790620 @default.
• W3120520904 hasConcept C185154212 @default.
• W3120520904 hasConcept C185592680 @default.
• W3120520904 hasConcept C2778019345 @default.
• W3120520904 hasConcept C2780386689 @default.
• W3120520904 hasConcept C2992130864 @default.
• W3120520904 hasConcept C502230775 @default.
• W3120520904 hasConcept C502942594 @default.
• W3120520904 hasConcept C55493867 @default.
• W3120520904 hasConcept C71924100 @default.
• W3120520904 hasConcept C98274493 @default.
• W3120520904 hasConceptScore W3120520904C108215921 @default.
• W3120520904 hasConceptScore W3120520904C126322002 @default.
• W3120520904 hasConceptScore W3120520904C178790620 @default.
• W3120520904 hasConceptScore W3120520904C185154212 @default.
• W3120520904 hasConceptScore W3120520904C185592680 @default.
• W3120520904 hasConceptScore W3120520904C2778019345 @default.
• W3120520904 hasConceptScore W3120520904C2780386689 @default.
• W3120520904 hasConceptScore W3120520904C2992130864 @default.
• W3120520904 hasConceptScore W3120520904C502230775 @default.
• W3120520904 hasConceptScore W3120520904C502942594 @default.
• W3120520904 hasConceptScore W3120520904C55493867 @default.
• W3120520904 hasConceptScore W3120520904C71924100 @default.
• W3120520904 hasConceptScore W3120520904C98274493 @default.
• W3120520904 hasFunder F4320321001 @default.

• next